The U.S. Department of Commerce has launched a new application process that could allow pharmaceutical companies to significantly reduce looming Section 232 tariffs if they commit to moving drug manufacturing operations to the United States.

Genentech has announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq and Tecentriq Hybreza for the adjuvant treatment of adults with muscle-invasive bladder cancer (MIBC) who show circulating tumor DNA molecular residual disease (ctDNA MRD) after bladder removal surgery. The approval marks the first FDA-cleared ctDNA-guided therapy approach for this aggressive cancer type.

TIGS, founded in 2017, is a non-profit research institute that aspires to develop solutions to challenges in human health and agriculture. TIGS is a unique initiative to support applications of cutting-edge science and technology in genetics and genomics to solve societal problems of the country. The most significant challenges that impede the achievement of health equity and nutrition security for all of India’s population require systematic evidence-based scientific advancements and technological solutions.